193 related articles for article (PubMed ID: 36455270)
1. Role of CDKN2A deletion in grade 2/3 IDH-mutant astrocytomas: need for selective approach in resource-constrained settings.
Suman S; Sharma R; Katiyar V; Mahajan S; Suri A; Sharma MC; Sarkar C; Suri V
Neurosurg Focus; 2022 Dec; 53(6):E17. PubMed ID: 36455270
[TBL] [Abstract][Full Text] [Related]
2. Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas.
Marker DF; Pearce TM
Acta Neuropathol Commun; 2020 Oct; 8(1):169. PubMed ID: 33081848
[TBL] [Abstract][Full Text] [Related]
3. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
4. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
[TBL] [Abstract][Full Text] [Related]
5. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].
Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323
[No Abstract] [Full Text] [Related]
6. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E
Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198
[TBL] [Abstract][Full Text] [Related]
7. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
[TBL] [Abstract][Full Text] [Related]
8. CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.
Yokoda RT; Cobb WS; Yong RL; Crary JF; Viapiano MS; Walker JM; Umphlett M; Tsankova NM; Richardson TE
J Neuropathol Exp Neurol; 2023 Sep; 82(10):845-852. PubMed ID: 37550258
[TBL] [Abstract][Full Text] [Related]
9. CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization.
Ranade M; Epari S; Shetty O; Dhanavade S; Chavan S; Sahay A; Sahu A; Shetty P; Moiyadi A; Singh V; Dasgupta A; Chatterjee A; Kannan S; Gupta T
J Neurooncol; 2024 Mar; 167(1):189-198. PubMed ID: 38265748
[TBL] [Abstract][Full Text] [Related]
10. A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
Xi S; Huang Q; Zeng J
J Neuropathol Exp Neurol; 2024 Jan; 83(2):125-130. PubMed ID: 38175671
[TBL] [Abstract][Full Text] [Related]
11. Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.
Kros JM; Rushing E; Uwimana AL; Hernández-Laín A; Michotte A; Al-Hussaini M; Bielle F; Mawrin C; Marucci G; Tesileanu CMS; Stupp R; Baumert B; van den Bent M; French PJ; Gorlia T
Neuro Oncol; 2023 Aug; 25(8):1443-1449. PubMed ID: 36571817
[TBL] [Abstract][Full Text] [Related]
12. Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.
Fortin Ensign SP; Jenkins RB; Giannini C; Sarkaria JN; Galanis E; Kizilbash SH
Neuro Oncol; 2023 Jan; 25(1):28-36. PubMed ID: 35973817
[TBL] [Abstract][Full Text] [Related]
13. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.
Reis GF; Pekmezci M; Hansen HM; Rice T; Marshall RE; Molinaro AM; Phillips JJ; Vogel H; Wiencke JK; Wrensch MR; Walsh KM; Perry A
J Neuropathol Exp Neurol; 2015 May; 74(5):442-52. PubMed ID: 25853694
[TBL] [Abstract][Full Text] [Related]
14. Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomas.
Gundogdu F; Babaoglu B; Soylemezoglu F
J Neuropathol Exp Neurol; 2024 Jan; 83(2):107-114. PubMed ID: 38109891
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of p16 expression pattern in diffuse gliomas.
Park JW; Kang J; Lim KY; Kim H; Kim SI; Won JK; Park CK; Park SH
J Pathol Transl Med; 2021 Mar; 55(2):102-111. PubMed ID: 33348944
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
[TBL] [Abstract][Full Text] [Related]
17. Qualitative and Quantitative Magnetic Resonance Imaging Phenotypes May Predict CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytomas: A Multicenter Study.
Park YW; Park KS; Park JE; Ahn SS; Park I; Kim HS; Chang JH; Lee SK; Kim SH
Korean J Radiol; 2023 Feb; 24(2):133-144. PubMed ID: 36725354
[TBL] [Abstract][Full Text] [Related]
18. Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A.
Leske H; Blakstad H; Lund-Iversen M; Skovholt EK; Niehusmann P; Ramm-Pettersen JT; Skogen K; Kongelf G; Sprauten M; Magelssen H; Brandal P
Neuropathology; 2023 Oct; 43(5):385-390. PubMed ID: 36754566
[TBL] [Abstract][Full Text] [Related]
19. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V
Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590
[TBL] [Abstract][Full Text] [Related]
20. Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report.
Takami H; Mukasa A; Takayanagi S; Koike T; Matsuura R; Ikemura M; Ushiku T; Yoshikawa G; Shibahara J; Tanaka S; Saito N
Brain Tumor Pathol; 2023 Jan; 40(1):26-34. PubMed ID: 36572828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
